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Introduction
Cellular senescence, which has traditionally been associated with
organism aging, has recently emerged as a determinant key related to
cancer chemotherapy. The Sir2 gene is associated with an increase in
longevity in yeasts, worms, flies and rodents. The human homolog, Sirt1,
is also involved in longevity, by inhibiting cellular senescence.
Studies carry out in tumor cells of neuroblastoma, osteosarcoma, breast
and ovary, resistant and sensitive to antineoplastic drugs, suggest that
the increase of Sirt1 expression may represent a general phenomenon
associated with resistance to chemotherapy, independent of cell type or
drug used to induce resistance. Thus, after analyzing tumor biopsies
after treating patients with chemotherapy, high amounts of Sirt1 have
been observed.
In addition, studies carried out on cisplatin-resistant cells show that Sirt1
is altered, suggesting that it might represent a molecule that responds to
stress, and might be related to chemotherapy.
Therefore, the identification of genes involved in senescence could have
a potential therapeutic utility for the prediction and/or prevention of
resistance to antineoplastic drugs.
Objectives
The aim of this work is to study the relationship between chronological
aging and acquired resistance to Cisplatin in the yeast Saccharomyces
cerevisiae.
Material and methods
Yeast strain and culture medium
The experiments were carried out with the haploid yeast strain
Saccharomyces cerevisiae WS8105-1C (genotype: MATalpha,
ade2, arg4-17, trp1-289, ura3-52) and with the resistant haploid
yeast strain to cisplatin Saccharomyces cerevisiae WS8105-1C-
R300cisPt. Yeast cells were grown in a liquid medium of SDC (2%
dextrose, 0,17% nitrogen base, 0,5% ammonium sulphate
[(NH4)2SO4], 0,15 % four-fold excess of the supplements ade,
arg, trp and ura) for the aging assay, and in a solid medium of
YPD (1 % Bacto-yeast extract, 2 % Bacto-peptone, 2 % dextrose
and 2 % Bacto-agar) for the cytotoxicity assay.
Chemicals
The antineoplastic drug used was cisplatin. The doses used were 0,
50, 100, 300, 500, 700 and 900 μg/ml for the cytotoxicity assay.
Experimental protocol
Aging assay: Yeast cells were cultured during five days on YPD-
agar plates at 30°C. Next, 1.5E+6 cells/ml were added to test
flask with 20 ml of SDC medium. They were cultured during 4 days
at 30°C, shaking at 300 rpm until they reached the stationary
phase. From that moment, the chronological aging phase began
and it was evaluated every two or three days by droptest, so six
10-fold serial dilutions from each sample were prepared and five-
microliter aliquots of each dilution were spotted onto YPD plates.
Finally, the surviving fraction was calculated.
Cytotoxicity test: Prior to exposures, yeast cells were cultured
during five days on YPD-agar plates at 30°C and then a loop was
suspended in 1000 μl of sterile water at a titer of 2E+7 cells/ml.
This quantity of cells was added to test tubes with different doses
of cisplatin and they were completed with sterile water until 1000
μl. Then, the tubes were cultured during 24 hours at 30°C and cells
washed twice with sterile water. For drop test assay, six 10-fold
serial dilutions from each sample were prepared and five-
microliter aliquots of each dilution were spotted onto YPD plates.
The same test was carried out to the resistant strain WS8105-1C-
R300cisPt.
Results and conclusion
The aging test lasted 31 days. It was observed that in the strain
WS8105-1C-R300cisPt (resistant to Cisplatin) there was a delay of
aging with respect to the wild type strain. In the wild strain there was a
sharp fall of the surviving fraction (FS). It was asymptotized on day 3
and with a FS value of 0.04. In contrast, in strain WS8105-1C-
R300cisPt the FS fall was less sudden, and it was asymptotized on day
15 with a FS value of 0.04.
The FS50 was calculated obtaining a result of 1.61 days for the wild
strain and a result of 5.22 days for the strain WS8105-1C-R300cisPt.
Therefore, there was a delay in aging in the strain WS8105-1C-
R300cisPt, with respect to the wild strain, of 3.24 days.
In the wild strain, the ID50 and ID90 values obtained were 90 μg/ml
and 300 μg/ml, respectively. In the resistant strain WS8105-1C-
R300cisPt, the ID50 and ID90 values obtained were 224 μg/ml (2.5
times more resistant with respect to the wild strain) and 735 μg/ml
(2.78 times more resistant with respect to the wild strain), respectively.
Thus, it was observed that for the ID50 and ID90 values there was an
increase in resistance associated with an increase in the aging delay,
with respect to the wild strain.
In conclusion, the strain WS8105-1C-R300cisPt (resistant to Cisplatin)
presents an increase in the chronological life cycle, producing a delay in
aging. This fact suggests that it is possible the expression of common
cellular and molecular mechanisms between the acquisition of resistance
to this drug and the delay in cellular aging. These results could have
important implications in tumor response to treatments.
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